$PCRX

Pacira BioSciences, Inc.

Pacira BioSciences is a biopharmaceutical company that develops and commercializes non-opioid pain treatments. Its products serve patients experiencing postsurgical pain and osteoarthritis-related pain, among other pain conditions. Pacira’s commercial products are EXPAREL, a long-acting injectable local analgesic for postsurgical pain; ZILRETTA, an extended-release joint injection indicated for osteoarthritis knee pain; and iovera, a handheld device that uses controlled cold to block pain signals from targeted nerves. Pacira also has a clinical development pipeline, including PCRX-201, a locally administered gene therapy in Phase 2 clinical development for osteoarthritis of the knee, and a proprietary high-capacity adenovirus vector platform. The company makes money by selling its products. Pacira BioSciences is headquartered in Brisbane, California.

0
1
3

No SEC Form 4 filings for $PCRX in the last 30 days.

See all $PCRX insider activity →
Med

Viatris Completes Acquisition of Pacira BioSciences

Viatris Inc. (VTRS) completed its acquisition of Pacira BioSciences (PCRX) for $36.50 per share. The deal, announced in October, aims to strengthen Viatris's U.S. pain management business. Pacira's shares will be delisted from Nasdaq, and Viatris expects the acquisition to add $90M-$100M in revenue for the rest of 2026.

Pacira BioSciences, Inc. (PCRX): RDF has the right to terminate the agreement for an uncured material breach by the Company, in connection with its bankruptcy or insolvency or if it directly…

Pacira BioSciences, Inc. (PCRX) filed an SEC Form 8-K — Regulation FD Disclosure. Item 7.01 Regulation FD Disclosure. As previously disclosed, pursuant to an agreement entered into between the Research Development Foundation (“RDF”) and a wholly-owned subsidiary of Pacira BioSciences, Inc. (the “Company” or “Pacira”), the Company was required to pay RDF a low

PCRX sentiment & insider activity

Over the past 7 days, AlphAI's AI scored 4 news stories mentioning PCRX (Pacira BioSciences, Inc.). Coverage has skewed bearish: 0 bullish, 1 neutral, and 3 bearish.

Recent PCRX coverage spans mergers & acquisitions, earnings and financial news.

What's driving PCRX

  • Pacira’s equity is effectively being acquired and removed from trading, making the remaining value largely offer-price driven.

    prnewswire.com · Nov 17, 2026

  • The reversal re‑imposes royalty liability, creating uncertainty over future cash flows and potential liability exposure.

    SEC EDGAR 8-K · Nov 12, 2026

  • Ingram Micro (INGM) will join the S&P SmallCap 600, replacing Pacira BioSciences (PCRX) after Viatris' (VTRS) acquisition of Pacira closes. INGM shares rose 4% in extended trading.

    seekingalpha.com · Nov 12, 2026

  • Viatris reported Q3 2026 revenue of $3.75 billion, missing estimates by 1.3%, but beat EPS and EBITDA expectations. The company raised full-year guidance for revenue, EPS, and EBITDA. Growth was driven by higher-margin products and new launches, while supply chain issues impacted some regions. The pending acquisition of Pacira BioSciences is expected to enhance EBITDA and expand product offerings.

    finance.yahoo.com · Nov 10, 2026

  • The earnings miss may trigger short-term price pressure.

    investing.com · Nov 8, 2026

AlphAI scores every news story that mentions PCRX with an AI model for sentiment and relevance, and aggregates insider trades from Pacira BioSciences, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $PCRX

Score
$VTRSMedAI 8/10M&A· acquirer · $36.5 · completed

Viatris Completes Acquisition of Pacira BioSciences

Viatris Inc. (VTRS) completed its acquisition of Pacira BioSciences (PCRX) for $36.50 per share. The deal, announced in October, aims to strengthen Viatris's U.S. pain management business. Pacira's shares will be delisted from Nasdaq, and Viatris expects the acquisition to add $90M-$100M in revenue for the rest of 2026.

Pacira BioSciences, Inc. (PCRX): RDF has the right to terminate the agreement for an uncured material breach by the Company, in connection with its bankruptcy or insolvency or if it directly…

Pacira BioSciences, Inc. (PCRX) filed an SEC Form 8-K — Regulation FD Disclosure. Item 7.01 Regulation FD Disclosure. As previously disclosed, pursuant to an agreement entered into between the Research Development Foundation (“RDF”) and a wholly-owned subsidiary of Pacira BioSciences, Inc. (the “Company” or “Pacira”), the Company was required to pay RDF a low

VTRS Q3 2026 deep dive: new product launches and Pacira acquisition shape outlook

Viatris reported Q3 2026 revenue of $3.75 billion, missing estimates by 1.3%, but beat EPS and EBITDA expectations. The company raised full-year guidance for revenue, EPS, and EBITDA. Growth was driven by higher-margin products and new launches, while supply chain issues impacted some regions. The pending acquisition of Pacira BioSciences is expected to enhance EBITDA and expand product offerings.

$PCRXHighAI 8/10M&A· target · $36.5 · definitive

Pacira BioSciences, Inc., a Delaware corporation, entered into the Agreement and Plan of Merger with Viatris Inc., a Delaware corporation, and Peach…

Pacira BioSciences, Inc. (PCRX) filed an SEC Form 8-K — Regulation FD Disclosure. Item 7.01. Regulation FD Disclosure. As previously disclosed, on October 8, 2026, Pacira BioSciences, Inc., a Delaware corporation (the “Company” or “Pacira”), entered into the Agreement and Plan of Merger (the “Merger Agreement”) with Viatris Inc., a Delaware corporation (“Viatr

Related tickers